Real-world laboratory practice patterns on next-generation-sequencing (NGS) technology in Latin America.

BELLI, CAROLINA B; BENDER, ANDREA; JAUK, FEDERICO; ALONSO, CRISTINA; ASINARI, MARIANA; RAHHAL, MARILINA; DE PALULA SABINO, ADRIANO; DUARTE, FERNANDO; CALADO, RODRIGO; CAMPEGHER, PAOLO VIDAL; YUNIS, JUAN; CORTES URREA, C; VILLEGAS FORTUNY, MAURICIO; ALAES VERSON, CARMEN; GOMEZ DE LEON, ANDRES; AYALA LUGO, ANA; OLMEDO, YARIBETH; ORTIZ GERRA, P; GARCIA, P; VALLADARES, XIMENA; GRILLÉ, SOFÍA

Marseille

Congreso; 17th International Congress of Myelodysplastic Syndromes; 2023

MDS Foundation

Molecular findings have increased their relevance as diagnostic and prognostic tools in myelodysplasticsyndromes. The access to multiple gene testing through high-throughput NGS is highly heterogeneous andlimited due to inadequate resources in Latin America (LA); however, it appears to be increasing. We aimed toassess the real-world laboratory practice patterns on NGS technology individualized among GrupoLatinoamericano de Mielodisplasia (GLAM) members.A 33-question survey (SurveyMonkey platform) was distributed and collected between March-2022/Jan-2023reviewing responsible professionals about aspect of the technology in their institutions.We realized and contacted 37 centers in 12 countries (figure) and 21/26 almost entirely responded to thesurvey. Private and National supported settings were almost equally distributed including Universities, Healthor Research institutions and Laboratories with an age-target practice covering 11/21 adults and 8-mixed. Start-up resources comprised from 12-governmental and 2-ASH supports to 11-private and 5-combinedinvestments including 4-ICAL projects. Most adopted 73%-Illumina platforms and 69%-commercial panelsincluding amplicons or capture technology developed mainly by 9-Illumina or 7-Sophia Genetics. Regardingpractical expertise, 9/21 expressed